We compared two recombinant α-galactosidases developed for enzyme replacement therapy for Fabry disease, agalsidase alfa and agalsidase beta, as to specific α-galactosidase activity, stability in ...
Jennewein has already made arrangements for the use of alternative strains lacking inducible b-galactosidase activity to ensure that it will be able to continue to provide 2'-FL to its customers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback